Surveillance for hepatocellular carcinoma in patients with non-alcoholic fatty liver disease: Universal or selective?

Maria Corina Plaz Torres, Giorgia Bodini, Manuele Furnari, Elisa Marabotto, Patrizia Zentilin, Mario Strazzabosco, Edoardo G. Giannini

Research output: Contribution to journalReview articlepeer-review


Hepatocellular carcinoma (HCC), the most frequent primary liver cancer, is the sixth most common cancer, the fourth leading cause of cancer-related deaths worldwide, and accounts globally for about 800,000 deaths/year. Early detection of HCC is of pivotal importance as it is associated with improved survival and the ability to apply curative treatments. Chronic liver diseases, and in particular cirrhosis, are the main risk factors for HCC, but the etiology of liver disease is rapidly changing due to improvements in the prevention and treatment of HBV (Hepatitis B virus) and HCV (Hepatitis C virus) infections and to the rising incidence of the metabolic syndrome, of which non-alcoholic fatty liver (NAFLD) is a manifestation. NAFLD is now a recognized and rapidly increasing cause of cirrhosis and HCC. Indeed, the most recent guidelines for NAFLD management recommend screening for HCC in patients with established cirrhosis. Screening in NAFLD patients without cirrhosis is not recommended; however, the prevalence of HCC in this group of NAFLD patients has been reported to be as high as 38%, a proportion significantly higher than the one observed in the general population and in non-cirrhotic subjects with other causes of liver disease. Unfortunately, solid data regarding the risk stratification of patients with non-cirrhotic NAFLD who might best benefit from HCC surveillance are scarce, and specific recommendations in this field are urgently needed due to the increasing NAFLD epidemic, at least in Western countries. To further complicate matters, liver ultrasonography, which represents the current standard for HCC surveillance, has a decreased diagnostic accuracy in patients with NAFLD, and therefore disease-specific surveillance tools will be required for the early identification of HCC in this population. In this review, we summarize the most recent evidence on the epidemiology and risk factors for HCC in patients with NAFLD, with and without cirrhosis, and the evidence supporting surveillance for early HCC detection in these patients, reviewing the potential limitations of currently recommended surveillance strategies, and assessing data on the accuracy of potential new screening tools. At this stage it is difficult to propose general recommendations, and best clinical judgement should be exercised, based on the profile of risk factors specific to each patient.

Original languageEnglish
Article number1422
Issue number6
Publication statusPublished - Jun 2020


  • Alpha-fetoprotein
  • Liver cancer
  • Risk factors
  • Steatohepatitis
  • Steatosis
  • Ultrasound

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'Surveillance for hepatocellular carcinoma in patients with non-alcoholic fatty liver disease: Universal or selective?'. Together they form a unique fingerprint.

Cite this